Advances in Melanoma: From Biology to Therapy

​Sept. 20-23, 2014
Loews Philadelphia
Philadelphia, Pa.

Conference Co-Chairpersons
Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Md.
Keith T. Flaherty, Massachusetts General Hospital, Boston, Mass.
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, Mass.

With so many recent advances in treating metastatic melanoma,
including approaches like immunotherapies, targeted therapies, and combination therapies, melanoma research is at a critical point where it is extremely important for the field to have a continuous exchange of information. Despite the success of various “targeted” inhibitors, therapeutic responses in melanoma patients are often short-lived due to rapidly acquired drug resistance. Therefore, it is essential that melanoma researchers translate the novel understanding of melanoma biology to decipher the mechanisms of innate and acquired drug resistance for the development of improved therapeutic options. To bridge the gap between scientists and clinician-scientists’ professional practice, this Special Conference will provide a platform for discussion and potential collaborations for the discovery of new therapeutic targets. 

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available